Verve Therapeutics, Inc.
VERV
$5.76
-$0.02-0.35%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 90.53% | 2.59% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 90.53% | 2.59% | |||
| Cost of Revenue | -353.21% | -2.05% | |||
| Gross Profit | 423.94% | 2.75% | |||
| SG&A Expenses | 1.89% | -4.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.42% | -2.68% | |||
| Operating Income | 1.48% | 3.28% | |||
| Income Before Tax | 0.13% | -0.58% | |||
| Income Tax Expenses | -29.81% | 57.58% | |||
| Earnings from Continuing Operations | 0.20% | -0.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.20% | -0.66% | |||
| EBIT | 1.48% | 3.28% | |||
| EBITDA | 1.43% | 3.53% | |||
| EPS Basic | 2.79% | -0.19% | |||
| Normalized Basic EPS | 2.73% | -0.11% | |||
| EPS Diluted | 2.79% | -0.19% | |||
| Normalized Diluted EPS | 2.73% | -0.11% | |||
| Average Basic Shares Outstanding | 2.65% | 0.48% | |||
| Average Diluted Shares Outstanding | 2.65% | 0.48% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||